Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Non-Controlling Interests (2020 - 2025)

ImmunityBio (IBRX) has disclosed Income from Non-Controlling Interests for 6 consecutive years, with -$14000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Non-Controlling Interests rose 17.65% to -$14000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$74000.0, a 8.64% increase, with the full-year FY2025 number at -$74000.0, up 8.64% from a year prior.
  • Income from Non-Controlling Interests was -$14000.0 for Q4 2025 at ImmunityBio, up from -$21000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$14000.0 in Q4 2025 to a low of -$1.1 million in Q2 2021.
  • A 5-year average of -$231100.0 and a median of -$85500.0 in 2022 define the central range for Income from Non-Controlling Interests.
  • Peak YoY movement for Income from Non-Controlling Interests: plummeted 122.88% in 2021, then skyrocketed 94.01% in 2024.
  • ImmunityBio's Income from Non-Controlling Interests stood at -$294000.0 in 2021, then soared by 62.24% to -$111000.0 in 2022, then surged by 80.18% to -$22000.0 in 2023, then rose by 22.73% to -$17000.0 in 2024, then increased by 17.65% to -$14000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Income from Non-Controlling Interests are -$14000.0 (Q4 2025), -$21000.0 (Q3 2025), and -$19000.0 (Q2 2025).